Chronic granulomatous disease: Clinical, molecular, and therapeutic aspects
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Chronic granulomatous disease (CGD) is a rare primary immunodeficiency caused by defects in the genes encoding any of the NADPH oxidase components responsible for the respiratory burst of phagocytic leukocytes. CGD is a genetically heterogeneous disease with an X‐linked recessive (XR‐CGD) form caused by mutations in the CYBB gene encoding the gp91 phox protein, and an autosomal recessive (AR‐CGD) form caused by mutations in the CYBA, NCF 1, NCF 2, or NCF 4 genes encoding p22 phox, p47 phox, p67 phox, and p40 phox, respectively. Patients suffering from this disease are susceptible to severe life‐threatening bacterial and fungal infections and excessive inflammation characterized by granuloma formation in any organ, for instance, the gastrointestinal and genitourinary tract. An early diagnosis of and the prompt treatment for these conditions are crucial for an optimal outcome of affected patients. To prevent infections, CGD patients should receive lifelong antibiotics and antifungal prophylaxis. These two measures, as well as newer more effective antimicrobials, have significantly modified the natural history of CGD, resulting in a remarkable change in overall survival, which is now around 90%, reaching well into adulthood. At present, hematopoietic stem cell transplantation (HSCT) is the only definitive treatment that can cure CGD and reverse organ dysfunction. Timing, donor selection, and conditioning regimens remain the key points of this therapy. In recent years, gene therapy (GT) for XR‐CGD has been proposed as an alternative to HSCT for CGD patients without a matched donor. After the failure of the first trials performed with retroviral vectors, some groups have proposed the use of regulated SIN‐lentiviral vectors targeting gp91 phox expression in myeloid cells to increase the safety and efficacy of the GT protocols.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
Bedard, K., & Krause, K.-H. (2007) · Physiological Reviews · doi:10.1152/physrev.00044.2005 · Cited by 6,989
Chronic Granulomatous Disease: Report on a National Registry of 368 Patients
Winkelstein, J. A., Marino, M. C., Johnston, R. B., Boyle, J., Curnutte, J., Gallin, J. I., Malech, H. L., Holland, S. M., Ochs, H., Quie, P., et al. (2000) · Medicine · doi:10.1097/00005792-200005000-00003 · Cited by 1,728
Killing activity of neutrophils is mediated through activation of proteases by K+ flux
Reeves, E. P., Lu, H., Jacobs, H. L., Messina, C. G. M., Bolsover, S., Gabella, G., Potma, E. O., Warley, A., Roes, J., & Segal, A. W. (2002) · Nature · doi:10.1038/416291a · Cited by 1,153
Residual NADPH Oxidase and Survival in Chronic Granulomatous Disease
Kuhns, D. B., Alvord, W. G., Heller, T., Feld, J. J., Pike, K. M., Marciano, B. E., Uzel, G., DeRavin, S. S., Priel, D. A. L., Soule, B. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007097 · Cited by 568 · cited 2×
“Indeed, a modest residual production of ROS is sufficient to confer a significantly less severe illness and a greater likelihood of long-term survival (23, 30).”
BackgroundDefective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease
Romani, L., Fallarino, F., De Luca, A., Montagnoli, C., D’Angelo, C., Zelante, T., Vacca, C., Bistoni, F., Fioretti, M. C., Grohmann, U., et al. (2008) · Nature · doi:10.1038/nature06471 · Cited by 535
Antifungal therapeutic drug monitoring: established and emerging indications
Andes, D., Pascual, A., & Marchetti, O. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00705-08 · Cited by 490
de Luca, A., Smeekens, S. P., Casagrande, A., Iannitti, R., Conway, K. L., Gresnigt, M. S., Begun, J., Plantinga, T. S., Joosten, L. A. B., van der Meer, J. W. M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322831111 · Cited by 313 · cited 1×
“Underlying mechanisms of hyperinflammation may include defective neutrophil apoptosis (4), skewed nuclear factor-kB signaling (5), upregulation of tumor necrosis factor alfa, interleukin (IL)-17, IL-6, and granulocyte colony-stimulating factor (6), prolonged IL-8 messenger RNA activation (7), impaired activation of Nr…”
BackgroundBustamante, J., Arias, A. A., Vogt, G., Picard, C., Galicia, L. B., Prando, C., Grant, A. V., Marchal, C. C., Hubeau, M., Chapgier, A., et al. (2011) · Nature Immunology · doi:10.1038/ni.1992 · Cited by 287
Lee, P. P. W., Chan, K.-W., Jiang, L., Chen, T., Li, C., Lee, T.-L., Mak, P. H. S., Fok, S. F. S., Yang, X., & Lau, Y.-L. (2008) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31815b494c · Cited by 158 · cited 1×
“Patients, however, develop severe localized, not disseminated, BCG infection and pulmonary, not miliary, tuberculosis (48).”
Background
Cited by
Albandar, J. M., Susin, C., & Hughes, F. J. (2018) · Journal of Periodontology · doi:10.1002/jper.16-0480 · Cited by 253
Albandar, J. M., Susin, C., & Hughes, F. J. (2018) · Journal of Clinical Periodontology · doi:10.1111/jcpe.12947 · Cited by 215
Pereira, C. P. M., Francis-Oliveira, J., Singulani, M. P., Ferreira, A. F. F., & Britto, L. R. G. (2023) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2023.578019 · Cited by 22
Metadata
- Authors
- Chiriaco, M., Salfa, I., Di Matteo, G., Rossi, P., & Finocchi, A.
- Venue
- Pediatric Allergy and Immunology
- Publisher
- Wiley
- Published
- 2016-01-21
- Volume
- 27
- Issue
- 3
- Pages
- 242-253
- ISSN
- 0905-6157 (ISSN-L)
- 1399-3038
- OpenAlex
- W2217159527
- Cited by
- 144
- References
- 9
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chronic granulomatous disease: Clinical, molecular, and therapeutic aspects. https://app.cochat.ai/papers/10.1111/pai.12527
- The paper
- Chiriaco, M., Salfa, I., Di Matteo, G., Rossi, P., & Finocchi, A. (2016). Chronic granulomatous disease: Clinical, molecular, and therapeutic aspects. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.12527
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.